GLP-1 receptor agonists effective for weight loss in obesity without diabetes

FHS
May 29, 2024
8:59 am

The benefit-harm balance of initiating Glucagon-like Peptide-1 (GLP-1) receptor agonists (RAs) versus a placebo intervention.

Ionis drug prevents swelling attacks caused by rare genetic disease in late-stage trials

Ionis Pharmaceuticals, a California company that pioneered a whole class of RNA-targeted medicines, reported on Friday that a pair of late-stage trials showed that its

May 31, 2024

Opinion | Congress Can Take Action to Prevent Older Adult Falls and Associated Opioid Use

Patel is a physical therapist and an advocate for policies that ensure access to physical therapy services. A common scenario we have all seen: an

April 15, 2024

Aledade Launches New Provider Recruitment Service for Practices

What You Should Know: – Aledade, the nation’s largest network of independent primary care, has launched a new service to accelerate practices’ ability to hire

September 11, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.